TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06393192

Intervention type: PROCEDURE
Intervention: Epidural analgesia (EA) only group
Description: The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.

Intervention type: PROCEDURE
Intervention: Quadratus lumborum block (QL2)
Description: 0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL

Intervention type: PROCEDURE
Intervention: Quadratus lumborum block 3(QL3)
Description: 0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL

Intervention type: PROCEDURE
Intervention: Quadratus lumborum block 2+3 QL(2+3)
Description: 0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
Study: NCT05849402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Active aiTBS
Description: Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham aiTBS
Description: Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
Study: NCT05109585

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
Description: evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
Description: evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
Study: NCT05567731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrashort GnRHa
Description: the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short GnRHa
Description: Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long GnRHa
Description: In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
Study: NCT05784701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSCV (Full-strength)
Description: TSCV (Full-strength)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSCV (Half-strength)
Description: TSCV (Half-strength)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typbar-TCV
Description: Typbar-TCV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06097234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelex Upp
Description: Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelex Upp
Description: Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
Study: NCT05556876

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein omega-3
Description: An oral supplement with a high content of protein and with essential fatty acids
Study: NCT05159843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise
Study: NCT05276804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
Study: NCT04731844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin plus Piperine
Description: Curcumin with piperine is a well-tolerated over-the-counter supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin plus Piperine
Description: Curcumin with piperine is a well-tolerated over-the-counter supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin plus Piperine
Description: Curcumin with piperine is a well-tolerated over-the-counter supplement.
Study: NCT05802693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
Description: Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
Study: NCT04595006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stimulation (CS)
Description: Subject wear cooling vest to stay cool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Browning Nutraceutical (BN)
Description: Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stimulation and Browning Nutraceutical (CSBN)
Description: Subject wear a cooling vest and consume 2000mg of curcumin
Study: NCT05346627

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Personalized and mixed training program
Description: Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
Study: NCT06372756

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning image reconstruction
Description: Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning image reconstruction
Description: Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
Study: NCT05457296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (capsule)
Description: salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone (capsule)
Description: salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
Study: NCT06330363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The laser device has sham light option that will be used.
Study: NCT05533814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel tablets.
Study: NCT01624532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1109 or Placebo of GC1109
Description: Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GC1109 or Placebo of GC1109
Description: Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks.
Study: NCT05450822

Intervention type: DRUG
Intervention: Levetiracetam
Description: Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models.

Intervention type: DRUG
Intervention: Levetiracetam
Description: Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models.

Intervention type: DRUG
Intervention: Levetiracetam Tablets
Description: Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.

Intervention type: DRUG
Intervention: Lamotrigine tablet
Description: Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
Study: NCT05071105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
Study: NCT05666401

Intervention type: PROCEDURE
Intervention: follicle diameter and duration of procedure
Description: to investigate if smaller follicles thrive embryos as the bigger follicles

Intervention type: PROCEDURE
Intervention: follicle diameter and duration of procedure
Description: to investigate if smaller follicles thrive embryos as the bigger follicles
Study: NCT04942275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-therapeutic imaging test
Description: The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
Study: NCT05172505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prefrontal tDCS
Description: 2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: prefrontal tDCS
Description: 2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
Study: NCT05686304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help money management program
Description: The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
Study: NCT05802381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein supplement
Description: 20 gram protein supplement per day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nutrition counseling
Description: nutrition counseling for guidance of food intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition counseling
Description: nutrition counseling for guidance of food intake
Study: NCT05796544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote self-care education
Description: The intervention group will receive a total of four remote educational sessions over 2 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person self-care education
Description: The active comparator group will receive a total of four in-person educational sessions over 2 months.
Study: NCT05053386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride for Injection
Description: After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
Study: NCT05001789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogMed
Description: 20 sessions of Cogmed working memory training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CogMed
Description: 20 sessions of Cogmed working memory training
Study: NCT06449157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation induction with parosmia
Description: The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted.
Study: NCT05731973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoablation
Description: Intercostal nerve cryoablation is applied during Nuss procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))
Description: Thoracic epidural is placed prior to Nuss procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
Description: Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)
Description: Opioids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)
Description: Opioids
Study: NCT05566899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagogastroduodenoscopy (EGD)
Description: After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC
Study: NCT06079411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality non-embodied
Description: the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality embodied
Description: the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises
Study: NCT05270889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab+Zanidatamab
Description: Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle.